Nancy Wysenski, EVP, Chief Commercial Officer at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 180,000 shares at $65.00 ($11.6M) on 2012-05-14, disclosed to the SEC on 2012-06-01.
Scheduled sale ($11.6M) by EVP, Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $64.27 | 179,628 | $11.5M | 99.8% |
| 2 | $65.00 | 372 | $24K | 0.2% |
| Total | $64.27 avg | 180,000 | $11.6M | 100% |
| Filing → |
| ALKS | BUY | 2019-03-18 | $270K | — | Filing → |
| VRTX | SELL | 2012-05-09 | $10.4M | — | Filing → |
| VRTX | SELL | 2012-01-23 | $224K | — | Filing → |